- Pfizer Inc PFE is reportedly in advanced talks to buy Global Blood Therapeutics Inc GBT for about $5 billion, bolster its portfolio and pipeline.
- Global Blood Therapeutics markets sickle-cell disease treatment, Oxbryta, which generated $194.7 million in revenue in 2021.
- Wall Street Journal says that Pfizer aims to seal a deal for GBT in the coming days, citing people familiar with the matter.
- Some people said the situation is still fluid, and other suitors are still in the mix.
- GBT announces its second-quarter results Monday.
- Bloomberg reported earlier this week that some large pharmaceutical companies are looking into a potential deal. Global Blood Therapeutics is reportedly working with advisors to evaluate potential takeover offers.
- At its current share price of $52.58, GBT has an enterprise value of $3.2 billion.
- Price Action: GBT shares are trading 41.1% higher during the market session on the last check Friday.
Loading...
Loading...
PFEPfizer Inc
$24.610.12%
Edge Rankings
Momentum
27.24
Growth
25.54
Quality
53.17
Value
34.60
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
